Guidant To Seek Review Of $425 Mil. Patent Suit Arbitration Award To Cordis
This article was originally published in The Gray Sheet
Executive Summary
Guidant stent sales will not be affected by a June 5 arbitration panel finding that the firm infringed Johnson &Johnson/Cordis' Palmaz-Schatz patents, Guidant says
You may also be interested in...
Cypher $470 Mil. Q4 Domestic Sales Double Size Of Cordis Unit
Cypher drug-eluting stent U.S. sales propelled a 99% Cordis revenue jump in the fourth quarter to $896 mil
Cypher $470 Mil. Q4 Domestic Sales Double Size Of Cordis Unit
Cypher drug-eluting stent U.S. sales propelled a 99% Cordis revenue jump in the fourth quarter to $896 mil
J&J/Cordis and Guidant arbitration
Ruling on Lau patent disputes, in which Guidant asserts infringement by Cordis' BX Velocity and Omni BX stents, is expected in early 2004. Guidant's Lau patent infringement claims against J&J/Cordis will be the second patent issue decided under the firms' April 2000 stent patent arbitration and cross-licensing deal. An Aug. 20 arbitration panel upheld a June decision to award J&J/Cordis $425 mil. for the infringement of its Palmaz-Schatz patents by Guidant's Multi-Link Duet coronary stent system (1The Gray Sheet" June 9, 2003, p. 22). Guidant set aside the money following the initial ruling and will incur no further costs due to the cross-licensing arrangement...